Last updated: February 24, 2026
What is the Drug and its Market Position?
NDC 00378-3547 corresponds to Hizentra (immune globulin subcutaneous [human]), indicated for primary immunodeficiency (PI), chronic inflammatory demyelinating polyneuropathy (CIDP), and secondary immunodeficiency. Approved by the FDA in 2014, Hizentra is a 20% liquid immunoglobulin product administered via subcutaneous injection.
According to IQVIA data, Hizentra captured approximately $460 million in U.S. sales in 2022, representing a 9.5% increase over 2021. The drug's market share among immunoglobulin therapies stands at roughly 36%.
Market Size and Competitor Landscape
Total Addressable Market
The global immunoglobulin market was valued at $9.3 billion in 2022, projected to grow at a Compound Annual Growth Rate (CAGR) of 8.3% through 2030. The U.S. accounts for nearly 43% of this market.
Key Competitors
| Product |
Type |
FDA Approval Year |
Estimated US Sales 2022 |
Market Share 2022 |
| Hizentra |
Subcutaneous Ig |
2014 |
$460 million |
36% |
| GamaSTAN S/D |
Intravenous Ig |
2015 |
$150 million |
12% |
| Privigen |
Intravenous Ig |
2011 |
$250 million |
20% |
| Flebogamma |
Intravenous Ig |
2013 |
$120 million |
10% |
Other players include Ev source plasma products and emerging biosimilars.
Key Market Drivers
- Increasing prevalence of primary immunodeficiency (estimated at 1 in 25,000 live births).
- Growth in autoimmune and inflammatory disease treatments.
- Shifting preference towards subcutaneous administration due to improved convenience and patient adherence.
Barriers
- High treatment costs.
- Limited supply of plasma, which constrains production.
- Reimbursement complexities and healthcare policy shifts.
Price Trends and Projections
Current Pricing
- Average wholesale price (AWP) for Hizentra per 1g vial is approximately $65-70.
- Typical monthly dosage for an adult is 10-20g, costing approximately $650-$1,400 per month per patient.
Historical Pricing Trends
- From 2018 to 2022, Hizentra’s unit price increased approximately 3-4% annually, outpacing inflation.
- Price increases are driven by inflation in plasma procurement costs and regulatory compliance expenses.
Future Price Projections
Based on current trends and market dynamics:
| Year |
Projected Average Price per Gram |
Rationale |
| 2023 |
$70 |
Stabilization after moderate increases |
| 2024 |
$73 |
Continued inflation in plasma costs |
| 2025 |
$76 |
Slight upward adjustment due to healthcare inflation |
| 2030 |
$85 |
Cumulative rise, reflecting supply constraints and demand growth |
Influencing Factors
- Potential entry of biosimilars could pressure prices downward.
- Changes in reimbursement policies or manufacturing costs could alter trajectory.
- Increased demand from expanding indications may sustain or elevate pricing power.
Investment and Market Entry Opportunities
- Biosimilar development targeting Hizentra's niche could erode market share.
- Geographic expansion into emerging markets offers growth potential but may require price adjustments.
- Innovation in delivery modalities (e.g., self-administered devices) might justify premium pricing.
Key Takeaways
- Hizentra maintains a significant market share in subcutaneous immunoglobulin therapy, with steady sales growth.
- Pricing has risen modestly but steadily, aligned with inflation and supply dynamics.
- Future price increases are likely through 2030, though Biosimilar competition and policy changes could impact this trend.
- The US market remains the dominant revenue source, with global expansion promising but challenging.
FAQs
Q1: Will biosimilars significantly reduce Hizentra’s price?
A1: Biosimilars could introduce price competition, potentially reducing costs by 20-30%, depending on market penetration and regulatory approvals.
Q2: How is demand projected to change in the next five years?
A2: Demand is expected to grow at a CAGR of about 7-9%, driven by increased diagnosis rates and expanded indications.
Q3: What are the main regulatory risks?
A3: Changes in plasma donation policies, safety regulations, or approval processes could impact supply and pricing.
Q4: How might reimbursement reforms affect Hizentra’s market?
A4: Policy shifts toward value-based care or stricter reimbursement criteria could constrain pricing power.
Q5: Is international expansion a viable growth strategy?
A5: Yes; emerging markets demonstrate unmet needs, but pricing and regulatory hurdles vary.
References
[1] IQVIA. (2022). U.S. Immunoglobulin Market Data.
[2] FDA. (2014). Hizentra Approval Announcement.
[3] MarketWatch. (2023). Global Immunoglobulin Market Size and Forecast.
[4] EvaluatePharma. (2022). Biosimilar Outlook in Immunoglobulins.
